Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU’s Medicines Authentication System Hits Implementation Problems At National Level

Executive Summary

The EU’s new medicines verification system, which is due to come into operation in February 2019, is experiencing delays, partly as a result of differences in member state approaches to the implementation of safety features on product packs. The European association representing generic and biosimilar firms has warned that any delays in setting up the system could lead to product shortages.

You may also be interested in...

‘Micro’ Firms Avoid UK Drug Verification System Fees, As More Countries Join European Hub

Very small companies are to be exempt from the fee for registering with the UK’s verification system that will be part of the future European scheme for checking the authenticity of medicines. Meanwhile, more countries have announced they have connected to the “hub” of the European Medicines Verification System.

Industry ‘Deeply Concerned’ Over Slow Progress With EU Drug Authentication System

Pharmaceutical industry stakeholders are “deeply concerned” about the slow rate of sign-ups to the future European medicines authentication system, according to the industry federation EFPIA. To encourage more companies to connect as early as possible, the joining fee is to increase this month. There are also wider worries about EU member state implementation of the system.

Updated EU Guide On Unique Identifiers May Impact Drug Distribution Strategies Post Brexit

The European Commission's updated guidance on the unique identifiers that are required under the Falsified Medicines Directive contains new information on several areas. It clarifies that the “decommissioned status” of an exported medicine that is brought back into the EU from a third country cannot be reversed and that such medicines should be fitted with a fresh identifier.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts